BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Yang L, Lin Y, Chang X, Wu H, Chen Y. Prognostic value of non-invasive serum Cytokeratin 18 detection in gastrointestinal cancer: a meta-analysis. J Cancer 2019;10:4814-23. [PMID: 31598152 DOI: 10.7150/jca.31408] [Reference Citation Analysis]
2 Yan CY, Fu ZJ, Liu GS, Li J, Sun CX. Value of heat shock protein 90 combined with alpha-fetoprotein in early diagnosis of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2021; 29(21): 1215-1221 [DOI: 10.11569/wcjd.v29.i21.1215] [Reference Citation Analysis]
3 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ocker M. Dissecting the immune cell landscape in hepatocellular carcinoma-are we understanding complexity? Ann Transl Med 2020;8:666. [PMID: 32617286 DOI: 10.21037/atm.2020.03.170] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Sun DW, An L, Huang HY, Sun XD, Lv GY. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true? Clin Transl Oncol 2021;23:82-91. [PMID: 32462395 DOI: 10.1007/s12094-020-02390-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Song S, Bai M, Li X, Gong S, Yang W, Lei C, Tian H, Si M, Hao X, Guo T. Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35234564 DOI: 10.1080/14737159.2022.2049248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Jiang Z, Shen L, Wang S, Wu S, Hu Y, Guo J, Fu L. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Med 2019;8:7278-87. [PMID: 31595711 DOI: 10.1002/cam4.2584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ali OM, El Amin HA, Sharkawy YL, Mohamed Ali AA, Kholef EFM, Elsewify WAE. Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma. Int J Gen Med 2020;13:193-200. [PMID: 32547160 DOI: 10.2147/IJGM.S253622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
10 Eissa M, Awad S, Barakat S, Saleh A, Rozaik S. Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis. Med J Armed Forces India 2021;77:331-6. [PMID: 34305287 DOI: 10.1016/j.mjafi.2020.11.013] [Reference Citation Analysis]
11 Pan X, Lin P, Feng F, Li J, Li Y, Dai W, Hu B, Yang X, Fan J, Li H, Li Y. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophys Rep 2020;6:19-32. [DOI: 10.1007/s41048-019-00102-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Song T, Li L, Wu S, Liu Y, Guo C, Wang W, Dai L, Zhang T, Wu H, Su B. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:583714. [PMID: 33777736 DOI: 10.3389/fonc.2021.583714] [Reference Citation Analysis]
13 Cavalluzzo B, Mauriello A, Ragone C, Manolio C, Tornesello ML, Buonaguro FM, Tvingsholm SA, Hadrup SR, Tagliamonte M, Buonaguro L. Novel Molecular Targets for Hepatocellular Carcinoma. Cancers (Basel) 2021;14:140. [PMID: 35008303 DOI: 10.3390/cancers14010140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
15 Wong M, Kim JT, Cox B, Larson BK, Kim S, Waters KM, Vail E, Guindi M. Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. Hepat Oncol 2021;8:HEP39. [PMID: 34765106 DOI: 10.2217/hep-2020-0034] [Reference Citation Analysis]
16 Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, Li C, Xia Y, Rao J, Dai X, Shao Q, Tang J, Li X, Shu Y. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Front Oncol 2022;12:909035. [DOI: 10.3389/fonc.2022.909035] [Reference Citation Analysis]
17 Ahmad M, Hameed Y, Khan M, Usman M, Rehman A, Abid U, Asif R, Ahmed H, Hussain MS, Rehman JU, Asif HM, Arshad R, Atif M, Hadi A, Sarfraz U, Khurshid U. Up-regulation of GINS1 highlighted a good diagnostic and prognostic potential of survival in three different subtypes of human cancer. Braz J Biol 2021;84:e250575. [PMID: 34852135 DOI: 10.1590/1519-6984.250575] [Reference Citation Analysis]
18 Ameri M, Salimi H, Eskandari S, Nezafat N. Identification of potential biomarkers in hepatocellular carcinoma: A network-based approach. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.100864] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Pomyen Y, Budhu A, Chaisaingmongkol J, Forgues M, Dang H, Ruchirawat M, Mahidol C, Wang XW; TIGER-LC Consortium. Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. Sci Rep 2021;11:12097. [PMID: 34103600 DOI: 10.1038/s41598-021-91560-1] [Reference Citation Analysis]
20 Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers (Basel) 2021;13:3510. [PMID: 34298722 DOI: 10.3390/cancers13143510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Kaur H, Bhalla S, Kaur D, Raghava GP. CancerLivER: a database of liver cancer gene expression resources and biomarkers. Database (Oxford) 2020;2020:baaa011. [PMID: 32147717 DOI: 10.1093/database/baaa012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Kaur H, Dhall A, Kumar R, Raghava GPS. Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data. Front Genet 2019;10:1306. [PMID: 31998366 DOI: 10.3389/fgene.2019.01306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
24 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Reference Citation Analysis]